SCHEMBL3977567

SCHEMBL3977567

COc1ccc(-c2coc(C(=O)O)c2-c2ccc(OC)cc2)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR4A2 P43354 1/20 0.51
SMN1; SMN2 Q16637 5/20 0.50
ALDH1A1 P00352 6/20 0.49
HPGD P15428 4/20 0.49
KDM4E B2RXH2 4/20 0.49
POLB P06746 1/20 0.49
CA1 P00915 1/20 0.44
CA2 P00918 1/20 0.44
MEN1 O00255 4/20 0.44
KMT2A Q03164 4/20 0.44
MAPT P10636 4/20 0.44
CYP2D6 P10635 3/20 0.44
CYP2C9 P11712 3/20 0.44
CYP2C19 P33261 3/20 0.44
TP53 P04637 3/20 0.44
CYP3A4 P08684 3/20 0.44
RAB9A P51151 3/20 0.44
NPC1 O15118 2/20 0.44
NFKB1 P19838 2/20 0.44
NFKB2 Q00653 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10892168 0.86 NR4A2 (0.53) NR4A2SMN1; SMN2ALDH1A1HPGDKDM4E
SCHEMBL28080958 0.85 NR4A2 (0.42) NR4A2SMN1; SMN2ALDH1A1HPGDKDM4E
SCHEMBL3982902 0.81 CA1 (0.46) SMN1; SMN2ALDH1A1HPGDKDM4EPOLB
SCHEMBL3982192 0.80 HSD17B10 (0.44) SMN1; SMN2ALDH1A1HPGDKDM4EPOLB
SCHEMBL3978078 0.80 ALDH1A1 (0.51) SMN1; SMN2ALDH1A1HPGDKDM4EPOLB
SCHEMBL2097892 0.80 HNF4A (0.43) SMN1; SMN2ALDH1A1HPGDKDM4EPOLB
SCHEMBL3975726 0.79 AURKA (0.40) SMN1; SMN2ALDH1A1KDM4EPOLBMAPT
SCHEMBL3982880 0.78 KMT2A (0.54) SMN1; SMN2ALDH1A1HPGDKDM4EPOLB
SCHEMBL989189 0.73 SMN1; SMN2 (0.64) SMN1; SMN2ALDH1A1HPGDKDM4EPOLB
SCHEMBL3977063 0.73 LMNA (0.45) SMN1; SMN2ALDH1A1HPGDMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7514452-B2 2-furancarboxylic acid hydrazides and pharmaceutical compositions containing the same DAINIPPON PHARMACEUTICAL CO., LTD (JP) 2009-04-07 US disclosed
US-20050171196-A1 2-Furancarboxylic acid hydrazides and pharmaceutical compositions containing the same DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2005-08-04 US disclosed
EP-1489077-A1 2-FURANCARBOXYLIC ACID HYDRAZIDES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME DAINIPPON PHARMACEUTICAL CO., LTD. (JP) 2004-12-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050171196-A1 2-Furancarboxylic acid hydrazides and pharmaceutical compositions containing the same GLP1R, GCGR, GPR119 NR4A2 211/4885SMN1; SMN2 3697/4885ALDH1A1 1389/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.